Fig. 3
Protein synthesis inhibition drives G6P synthesis. a TXNIP mRNA levels in HeLa cells treated with CHX and the electron transport chain inhibitor metformin (Met, 5 mM) or oligomycin (Olig, 1 μM) for 16 h. b TXNIP mRNA levels following a 16-h RocA treatment of HeLa cells transfected with pool of siRNA specific for ATP5I (siATP5I) or a pool of scrambled control siRNAs (siSCRM). c A mitochondrial-targeted ATP FRET biosensor (mitATEAM) was used to determine relative mtATP levels in HeLa cells treated with the protein synthesis inhibitor RocA for up to 6 h. Relative mtATP was determined as the ratio of FRET to CFP intensities. d TXNIP mRNA levels following a 16-h RocA treatment (100 nM) of HeLa cells expressing wildtype mouse VDAC1 (mVDAC1) or VDAC1(E72Q), which cannot bind Hexokinase II. e TXNIP mRNA levels in HeLa cells treated for 16 h with CHX or methyl-jasmonate (3 mM). f Heatmap showing relative metabolite levels from HeLa cells treated with CHX for 16 h. Metabolite levels were assessed through GC-MS. f Log2(fold-change) of glycolytic and TCA cycle intermediates from HeLa cells treated with CHX for 16 h, relative to control DMSO treatment. TXNIP mRNA levels were determined using RT-qPCR